Aarti Drugs reported a consolidated PAT of Rs 195 crore for FY 2025-26, up 16% year-on-year, driven by new facility commercialization and an increased revenue share from regulated markets. Despite first-half margin pressures from start-up costs and geopolitical headwinds, the company successfully scaled its Sayakha and Tarapur facilities. Management announced a leadership transition effective October 2026, with Rashesh C. Gogri taking over as Chairman and Adhish P. Patil as Managing Director. Investors should watch for continued capacity utilization improvements and the company’s Rs 1,000 crore formulations business target.
Aarti Drugs FY26 PAT Up 16% to Rs 195 Crore
Consolidated PAT stood at Rs 195 crore for FY26 compared to Rs 168 crore in FY25, while total revenue grew 6.8% to Rs 2,568 crore.
Reader Takeaway: Strong PAT growth and operational scaling at Sayakha provide upside; however, geopolitical risks and start-up costs persist.
What just happened
Aarti Drugs concluded FY 2025-26 with a 16% increase in consolidated profit after tax (PAT) to Rs 195 crore. The company successfully moved past a multi-year investment phase, with the Sayakha Methylamines facility and the USFDA-approved oncology formulations plant now operational. The firm saw its revenue mix shift, with regulated markets now contributing 73% of total revenue, up from 66% in the previous fiscal year.
Why this matters
The commercialization of high-entry-barrier facilities allows Aarti Drugs to shift its product mix toward higher-margin segments. Despite challenging pricing environments and geopolitical tensions affecting raw material supply chains, the company maintained an EBITDA of Rs 312 crore. The scaling of the Sayakha facility to a 1,000 tonnes-per-month run rate by March 2026 demonstrates operational momentum that investors will watch for sustained profitability.
Leadership Transition
In a major board change, Shri Prakash M. Patil will retire on October 1, 2026. The board has designated Shri Rashesh C. Gogri as the new Chairman, while Shri Adhish P. Patil will step into the role of Managing Director. This transition aims to streamline leadership as the company targets a Rs 1,000 crore milestone for its formulations franchise.
Risks to watch
Management cited start-up costs as a drag on H1 profitability. Geopolitical tensions in West Asia remain a critical monitor, particularly concerning the availability and pricing of raw materials like ammonia. While the balance sheet currently shows a record-low debt-to-equity ratio, market volatility and raw material inflation could impact margins in the short term.